[1]邹小白,郑旭琴,张永明.代谢重编程在甲状腺肿瘤发生发展中的作用研究进展[J].国际内分泌代谢杂志,2022,42(06):461-464.[doi:10.3760/cma.j.cn121383-20210428-04088]
　Zou Xiaobai,Zheng Xuqin,Zhang Yongming.Research progress on the role of metabolic reprogramming in the development of thyroid tumors[J].International Journal of Endocrinology and Metabolism,2022,42(06):461-464.[doi:10.3760/cma.j.cn121383-20210428-04088]
点击复制

代谢重编程在甲状腺肿瘤发生发展中的作用研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年06期
页码:
461-464
栏目:
综述
出版日期:
2022-11-20

文章信息/Info

Title:
Research progress on the role of metabolic reprogramming in the development of thyroid tumors
作者:
邹小白1; 郑旭琴2; 张永明1
1安徽省第二人民医院内分泌科,合肥 230041; 2南京医科大学第一附属医院内分泌科 210029
Author(s):
Zou Xiaobai1;  Zheng Xuqin2;  Zhang Yongming1
1Department of Endocrinology, Anhui No.2 Provincial People's Hospital, Hefei 230041, China; 2Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
关键词:
代谢重编程;  糖酵解;  甲状腺肿瘤
Keywords:
Metabolic reprogramming;  Glycolysis;  Thyroid tumor
DOI:
10.3760/cma.j.cn121383-20210428-04088
摘要:
代谢重编程是细胞为满足能量需求,通过改变代谢模式促进细胞增殖、生长及生物合成的过程,该过程目前已被证实在多种疾病的发生及进展中发挥着重要作用。甲状腺肿瘤为一种常见的内分泌肿瘤,启动代谢重编程促进细胞生长、增殖及侵袭的特征目前成为研究热点。代谢重编程中的一些代谢分子的表达水平与甲状腺肿瘤的预后密切相关。
Abstract:
Metabolic reprogramming is a process in which cells promote cell proliferation, growth and biosynthesis by changing metabolic patterns to meet energy requirements, and this process has been shown to play a crucial role in the occurrence and progression of a variety of diseases. Thyroid tumor is a common endocrine tumor, the characteristic of activating metabolic reprogramming to promote cell growth, proliferation and invasion has become a research hotspot at present. The expression levels of some metabolites involved in metabolic reprogramming are closely related to the prognosis of thyroid tumors.

参考文献/References:

[1] Nakagawa T,Lanaspa MA,Millan IS,et al.Fructose contributes to the Warburg effect for cancer growth[J].Cancer Metab,2020,8:16.DOI:10.1186/s40170-020-00222-9.
[2] Martinez-Outschoorn UE,Peiris-Pagés M,Pestell RG,et al.Cancer metabolism:a therapeutic perspective[J].Nat Rev Clin Oncol,2017,14(2):113.DOI:10.1038/nrclinonc.2017.1.
[3] Boroughs LK,Deberardinis RJ.Metabolic pathways promoting cancer cell survival and growth[J].Nat Cell Biol,2015,17(4):351-359.DOI:10.1038/ncb3124.
[4] 陈璐,高威.肿瘤酸性微环境的形成机制及其对肿瘤进展的影响[J].肿瘤,2019,39(2):140-145.DOI:10.3781/j.issn.1000-7431.2019.55.490.
[5] Nilubol N."Cutting the support" to improve treatment efficacy in thyroid cancer by targeting tumor microenvironment[J].J Clin Endocrinol Metab,2022.107(4):e1758-e1559.DOI:10.1210/clinem/dgab685.
[6] Bao L,Xu T,Lu X,et al.Metabolic reprogramming of thyroid cancer cells and crosstalk in their microenvironment[J].Front Oncol,2021,11:773028.DOI:10.3389/fonc.2021.773028.
[7] Nahm JH,Kim HM,Koo JS.Glycolysis-related protein expression in thyroid cancer[J].Tumour Biol,2017,39(3):1-10.DOI:10.1177/1010428317695922.
[8] Heydarzadeh S,Moshtaghie AA,Daneshpoor M,et al.Regulators of glucose uptake in thyroid cancer cell lines[J].Cell Commun Signal,2020,18(1):83.DOI:10.1186/s12964-020-00586-x.
[9] Tian J,Guo F,Chen Y,et al.Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation[J].Cancer Lett,2019,448:1-10.DOI:10.1016/j.canlet.2019.01.002.
[10] Zhang C,Lv B,Yi C,et al.Genistein inhibits human papillary thyroid cancer cell detachment,invasion and metastasis[J].J Cance,2019,10(3):737-748.DOI:10.7150/jca.28111.
[11] 李宇,徐瑾,贺会清.二甲双胍抑制甲状腺乳头状癌的相关作用机制[J].实用医学杂志,2019,35(13):2185-2189.DOI:10.3969/j.issn.1006-5725.2019.13.034.
[12] Huang J,Gao W,Liu H,et al.Up-regulated ANP32E promotes the thyroid carcinoma cell proliferation and migration via activating AKT/Mtor/HK2-mediated glycolysis[J].Gene,2020,750:144681.DOI:10.1016/j.gene.2020.144681.
[13] Wang SY,Wei YH,Shieh DB,et al.2-deoxy-D-glucose can complement doxorubicin and sorafenib to suppress the growth of papillary thyroid carcinoma cells[J].PLoS One,2015,10(7):e0130959.DOI:10.1371/journal.pone.0130959.
[14] Coelho RG,Cazarin JM,Cavalcanti de Albuquerque JP,et al.Differential glycolytic profile and Warburg effect in papillary thyroid carcinoma cell lines[J].Oncol Rep,2016,36(6):3673-3681.DOI:10.3892/or.2016.5142.
[15] You L,Zhu H,Wang C,et al.Scutellarin inhibits Hela cell growth and glycolysis by inhibiting the activity of pyruvate kinase M2[J].Bioorg Med Chem Lett,2017,27(24):5404-5408.DOI:10.1016/j.bmcl.2017.11.011.
[16] Fan Q,Yang L,Zhang X,et al.Autophagy promotes metastasis and glycolysis by upregulating MCT1 expression and Wnt/β-catenin signaling pathway activation in hepatocellular carcinoma cells[J].J Exp Clin Canc Res,2018,37(1):9-19.DOI:10.1186/s13046-018-0673-y.
[17] 王蓉,罗军,魏莉,等.单羧酸转运蛋白1、4在甲状腺乳头状癌中的表达及其相关性研究[J].解放军预防医学杂志,2019,37(11):126-127.
[18] Beloueche-Babari M,Wantuch S,Casals Galobart T,et al.MCT1 inhibitor AZD3965 increases mitochondrial metabolism,facilitating Ccombination therapy and Nnoninvasive magnetic resonance spectroscopy[J].Cancer Res,2017,77(21):5913-5924.DOI:10.1158/0008-5472.CAN-16-2686.
[19] 吴昊,甘蕾,夏瑞,等.3-溴丙酮酸抑制人肝癌细胞株糖酵解的研究[J].中华实验外科杂志,2018,35(9):1663-1666.DOI:10.3760/cma.j.issn.1001-9030.2018.09.024.
[20] Liu CL,Yang PS,Wang TY,et al.PGC1α downregulation and glycolytic phenotype in thyroid cancer[J].J Cancer,2019,10(16):3819-3829.DOI:10.7150/jca.30018.
[21] Gao Y,Yang F,Yang XA,et al.Mitochondrial metabolism is inhibited by the HIF1α-MYC-PGC-1β axis in BRAFV600E thyroid cancer[J].FEBS J,2019,286(7):1420-1436.DOI:10.1111/febs.14786.
[22] Wang W,Wong CW.Statins enhance peroxisome proliferator-activated receptor gamma coactivator-1alpha activity to regulate energy metabolism[J].J Mol Med(Berl),2010,88(3):309-317.DOI:10.1007/s00109-009-0561-1.

备注/Memo

备注/Memo:
通信作者:邹小白, Email: zxbzh1991@163.com
更新日期/Last Update: 2022-12-01